Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Endo-Atropine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.91 |
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.91 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.91 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.91 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.91 |
| ▸ | HTR2C | P28335 | 2/20 | 0.91 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.91 |
| ▸ | BLM | P54132 | 2/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.91 |
| ▸ | MEN1 | O00255 | 1/20 | 0.91 |
| ▸ | POLB | P06746 | 1/20 | 0.91 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.91 |
| ▸ | HRH1 | P35367 | 1/20 | 0.91 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.91 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atropine SCHEMBL27510472 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL3050622 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL28275981 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Hyoscyamine SCHEMBL34273 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL1411666 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL31133 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL2406485 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL31132 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL34274 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL34275 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097087-A1 | RECOMBINANT FUSION POLYPEPTIDES FOR SECRETING SOLUBLE, HETEROLOGOUS CARGO | NOVOME BIOTECHNOLOGIES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20250049881-A1 | FORMULATIONS OF GUANYLATE CYCLSE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2025-02-13 | — | — | US | disclosed |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-11-19 | — | — | US | disclosed |
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2024-08-29 | — | — | US | disclosed |
| WO-2024064918-A2 | RECOMBINANT FUSION POLYPEPTIDES FOR SECRETING SOLUBLE, HETEROLOGOUS CARGO | NOVOME BIOTECHNOLOGIES, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2023-10-26 | — | — | US | disclosed |
| EP-3708179-B1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023094817-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ATROPINE | OREXO AB (SE) | 2023-06-01 | — | — | WO | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | CHRM1 897/4885CHRM2 1277/4885CHRM3 654/4885 |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CHRM1 897/4885CHRM2 1277/4885CHRM3 654/4885 |
| US-20260097087-A1 | RECOMBINANT FUSION POLYPEPTIDES FOR SECRETING SOLUBLE, HETEROLOGOUS CARGO | IAPP, VIP, NSF | CHRM1 4636/4885CHRM2 4581/4885CHRM3 4706/4885 |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CHRM1 897/4885CHRM2 1277/4885CHRM3 654/4885 |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CHRM1 897/4885CHRM2 1277/4885CHRM3 654/4885 |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CHRM1 897/4885CHRM2 1277/4885CHRM3 654/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | CHRM1 897/4885CHRM2 1277/4885CHRM3 654/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | CHRM1 897/4885CHRM2 1277/4885CHRM3 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.